DPYDGenotyping to Predict Adverse Events Following Treatment With Fluorouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon Cancer
Open Access
- 1 May 2016
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 2 (5) , 655-662
Abstract
Since the 1990s, fluorouracil-based adjuvant chemotherapy has been the standard of care for patients with stage III colon cancer (CC) after curative surgical resection. The MOSAIC study1 showed significant improvements in disease-free survival and overall survival in patients with stage III CC receiving infused fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) compared with fluorouracil and leucovorin alone, with 5-year disease-free survival of 66.4% and 6-year overall survival of 72.9% in the experimental group. This degree of benefit was confirmed by the NSABP C-07 study2 in patients receiving FLOX (bolus fluorouracil, leucovorin, and oxaliplatin) compared with those receiving bolus fluorouracil and leucovorin alone. As in the metastatic setting, the addition of oxaliplatin to fluorouracil therefore results in better efficacy compared with fluorouracil alone but also increases overall and severe adverse events (AEs).1,3Keywords
This publication has 5 references indexed in Scilit:
- Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000–05): an open-label, randomised, phase 3 trialThe Lancet Oncology, 2011
- Faculty Opinions recommendation of PLINK: a tool set for whole-genome association and population-based linkage analyses.2009
- Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin As Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer: Results From NSABP C-07Journal of Clinical Oncology, 2007
- Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracilEuropean Journal of Cancer, 2004
- Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trialCancer, 1995